COPD Is/Is Not a Systemic Disease?

Intro -- COPD IS/IS NOT A SYSTEMIC DISEASE? -- COPD IS/IS NOT A SYSTEMIC DISEASE? -- CONTENTS -- INTRODUCTION -- Chapter 1 COPD IS A SYSTEMIC DISEASE - THE PATHPHYSIOLOGICAL BASIS -- ABSTRACT -- INTRODUCTION -- Systemic Inflammation -- Genetics and Epigenetics -- Vascular Abnormalities -- Immunology -- Repair Failure -- Infections -- CONCLUSION -- REFERENCES -- Chapter 2 COPD IS NOT A SYSTEMIC DISEASE - THE PATHOPHYSIOLOGICAL BASIS -- ABSTRACT -- INTRODUCTION -- DIAGNOSIS AND STAGING OF COPD -- PATHOPHYSIOLOGY -- Small Airways Disease -- Pulmonary Hyperinflation -- Ventilation-perfusion -- CONCLUSION -- REFERENCES -- Chapter 3 DISCUSSION ON THE PATHOPHYSIOLOGICAL BASIS OF COPD -- Chapter 4 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? REALITY -- ABSTRACT -- INTRODUCTION -- Origin of Systemic Inflammation in COPD -- Consequences of systemic inflammation in COPD -- CONCLUSION -- REFERENCES -- Chapter 5 COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? MYTH -- ABSTRACT -- INTRODUCTION -- GENERAL CONSIDERATIONS -- SMOKING AND 'SYSTEMIC INFLAMMATION' -- STABLE COPD AND 'SYSTEMIC INFLAMMATION' -- ACUTE EXACERBATIONS AND 'SYSTEMIC INFLAMMATION' -- THE EFFECT OF COPD TREATMENT ON 'SYSTEMIC INFLAMMATION' -- CONCLUSION -- REFERENCES -- Chapter 6 DISCUSSION ON COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? -- Chapter 7 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST? YES -- ABSTRACT -- INTRODUCTION -- PULMONARY BIOMARKERS IN STABLE COPD -- SYSTEMIC INVOLVEMENT IN COPD -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: MORE THAN SYSTEMIC INFLAMMATION -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD: HOW TO PROGRESS? LESSONS LEARNED FROM HEART FAILURE -- BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: HOW TO PROGRESS? -- a. CC-16 -- b. Surfactant Protein D (SP-D) -- c. Cachexia -- d. Osteoporosis -- CONCLUSION.

REFERENCES -- Chapter 8 BIOMARKERS OF SYSTEMIC INOLVEMENT IN STABLE COPD: DO THEY EXIST? NO -- ABSTRACT -- INTRODUCTION -- Inflammation in COPD Concomitant Diseases -- The Role of "Inflammaging" -- Systemic Biomarkers Involvement in COPD -- The Controversial Meaning of Steroid Therapy in COPD -- Lung Specific Biomarkers in COPD: New Frontiers? -- CONCLUSION -- REFERENCES -- Chapter 9 DISCUSSION ON BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD: DO THEY EXIST? -- Chapter 10 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE MORNING, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS -- I. PATHOPHYSIOLOGICAL BASIS -- II. COPD AND SYSTEMIC INFLAMMATION: MYTH OR REALITY? -- III. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN STABLE COPD - DO THEY EXIST? -- Chapter 11 BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE? YES -- ABSTRACT -- INTRODUCTION -- 1. WHAT IS AN EXACERBATION OF COPD? -- 2. WHAT IS A BIOMARKER? -- 3. SYSTEMIC INVOLVEMENT AT EXACERBATION OF COPD -- 4. WHAT DO WE WANT A SYSTEMIC EXACERBATION BIOMARKER TO ASSESS? -- 5. HOW SHOULD WE ASSESS THE EFFICACY OF A BIOMARKER IN ACHIEVING THESE AIMS? -- 6. A BIOMARKER TO CONFIRM EXACERBATION? -- 7. A BIOMARKER TO INFORM ON EXACERBATION AETIOLOGY? -- 8. A BIOMARKER TO INFORM ON EXACERBATION SEVERITY? -- 9. A BIOMARKER TO PREDICT POST-EXACERBATION EVENTS? -- CONCLUSION -- REFERENCES -- Chapter 12 IS THERE EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS? NO -- ABSTRACT -- INTRODUCTION -- a) Underlying Baseline Inflammation due to Comorbid Conditions -- b) Etiology of Exacerbations -- c) Impact of Treatment -- CONCLUSION -- REFERENCES -- Chapter 13 DISCUSSION ON: IS THERE OVERWHELMING EVIDENCE FROM BIOMARKERS OF SYSTEMIC INVOLVEMENT IN COPD EXACERBATIONS?.

Chapter 14 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? COPD - A PRIMARILY RESPIRATORY DISEASE WITH IMPORTANT SYSTEMIC CONSEQUENCES -- ABSTRACT -- INTRODUCTION -- SYSTEMIC INFLAMMATION -- Acute Phase Proteins -- CRP -- COPD AND IMPAIRED FUNCTIONAL CAPACITY -- Pulmonary Factors -- Systemic Factors -- MUSCLE DYSFUNCTION AND MALNUTRITION IN COPD -- Mechanisms -- Treatment -- CARDIOVASCULAR DISEASE -- Coronary Artery Disease and Atherosclerosis -- Heart Failure -- Pulmonary Arterial Hypertension -- Cardiac Function at Rest -- Cardiac Function During Exercise -- Arterial Stiffness and Endothelial Function -- ANEMIA -- OSTEOPOROSIS -- Mechanisms -- Therapy -- DEPRESSION -- Mechanisms -- Treatment -- LUNG CANCER -- Mechanisms -- Therapy -- OBSTRUCTIVE SLEEP APNOEA -- IMPLICATIONS FOR THERAPY -- REFERENCES -- Chapter 15 SCIENCE AT THE BEDSIDE. IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC DISEASE WITH PULMONARY SYMPTOMS? A CASE REPORT -- ABSTRACT -- CASE REPORT -- THE CASE FOR CONSIDERING COPD AS A SYSTEMIC DISEASE WITH PROMINENT RESPIRATORY MANIFESTATIONS -- Mrs. CG -- PROMINENT SYSTEMIC DISEASE AND PREDICTABLE CO-MORBIDITY IN COPD -- COPD AND SYSTEMIC INFLAMMATION -- An Inflammatory Respiratory Disease with Systemic Spill-over -- A Systemic Disease Involving Primarily the Lungs -- A Vicious Circle -- SYSTEMIC INFLAMMATION IN STABLE COPD -- SYSTEMIC INFLAMMATION AND ITS EFFECT ON THE TREATMENT OF MRS. CG -- SUMMARY -- REFERENCES -- Chapter 16 DISCUSSION ON: IS COPD A RESPIRATORY DISEASE WITH PROMINENT SYSTEMIC IMPLICATIONS OR A SYSTEMIC CONDITION WITH PULMONARY SYMPTOMS? -- Chapter 17 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? RESPIRATORY APPROACH -- ABSTRACT -- REFERENCES.

Chapter 18 APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? SYSTEMIC APPROACH -- ABSTRACT -- INTRODUCTION -- COMPLEX CHRONIC COMORBIDITIES -- CLINICAL GUIDELINES FOR CORD AND CHRONIC DISEASES -- EFFECTS OF TREATMENT OF CORD ON ITS COMORBIDITIES -- Smoking Cessation -- Rehabilitation -- Supplemental Oxygen Therapy -- Pharmacologic Treatment -- EFFECT OF TREATMENT OF COMORBIDITIES ON COPD -- Statins -- -Blockers -- CONCLUSION -- REFERENCES -- Chapter 19 DISCUSSION ON THE APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? -- Chapter 20 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - MYTH -- ABSTRACT -- INTRODUCTION -- MYTH 1: STEPWISE APPROACH TO TREATMENT OF COPD -- MYTH 2: SHORT-ACTING BRONCHODILATOR FOR MILD COPD -- MYTH 3: INHALED CORTICOSTEROIDS FOR SEVERE COPD -- TREATMENT OF COPD ACCORDING TO THE PATIENT CHARACTERISTICS -- THE REASON FOR THE CONFUSION -- CONCLUSION -- REFERENCES -- Chapter 21 GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? - REALITY -- ABSTRACT -- INTRODUCTION -- Source of Guidelines -- Methods -- Conflicts of Interest -- COPD GUIDELINES -- Reality or Myth -- Systemic Features and COPD Guidelines -- IMPACT OF GUIDELINES IN PATIENTS WITH CO-MORBIDITIES -- CONCLUSION -- REFERENCES -- Chapter 22 DISCUSSION ON: GUIDELINES AND CLINICAL PRACTICE: MYTH OR REALITY? -- Chapter 23 DISCUSSION IN-DEPTH OF TOPICS PRESENTED IN THE AFTERNOON, WITH A VIEW TO REACHING A CONSENSUS OR DISSENSUS -- IV. BIOMARKERS OF SYSTEMIC INVOLVEMENT IN ACUTE EXACERBATIONS OF COPD: IS THERE OVERWHELMING EVIDENCE? -- V. APPROACH TO COPD: RESPIRATORY OR SYSTEMIC TREATMENT? -- VI. GUIDELINES AND CLINICAL PRACTICE -- GOALS OF CLINICAL PRACTICE GUIDELINES -- PROBLEMS WITH CURRENT COPD GUIDELINES -- Chapter 24 SUMMING UP AND FINAL REMARKS -- INDEX.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.